Author: Czajka, Timothy F.; Vance, David J.; Mantis, Nicholas J.
Title: Slaying SARS-CoV-2 One (Single-Domain) Antibody at a Time Cord-id: jdq859xc Document date: 2020_12_16
ID: jdq859xc
Snippet: Camelid-derived and synthetic single-domain antibodies (sdAbs) are emerging as potent weapons against the novel coronavirus, SARS-CoV-2. SdAbs are small, compact, thermostable immunoglobulin elements capable of binding targets with sub-nanomolar affinities. By leveraging the power of phage- and yeast surface-display technologies, rare sdAbs can be isolated from highly diverse and complex antibody libraries. Once in hand, sdAbs can be engineered to improve binding affinity, avidity, target specif
Document: Camelid-derived and synthetic single-domain antibodies (sdAbs) are emerging as potent weapons against the novel coronavirus, SARS-CoV-2. SdAbs are small, compact, thermostable immunoglobulin elements capable of binding targets with sub-nanomolar affinities. By leveraging the power of phage- and yeast surface-display technologies, rare sdAbs can be isolated from highly diverse and complex antibody libraries. Once in hand, sdAbs can be engineered to improve binding affinity, avidity, target specificities, and bio-distribution. In this Opinion piece, we highlight a series of sophisticated studies describing the identification of ultrapotent sdAbs directed against the receptor binding domain (RBD) of the SARS-CoV-2 Spike protein. We discuss the possible applications of these antibodies in the global fight against COVID-19.
Search related documents:
Co phrase search for related documents- active site and low affinity: 1, 2, 3, 4, 5, 6
- active site and low nanomolar: 1, 2, 3, 4
- acute ards respiratory distress syndrome and low affinity: 1
- acute ards respiratory distress syndrome and lung histopathology: 1, 2, 3, 4, 5, 6, 7
- acute ards respiratory distress syndrome and lung limit: 1, 2, 3, 4, 5, 6, 7, 8, 9
Co phrase search for related documents, hyperlinks ordered by date